The Institute for Clinical and Economic Review (ICER) frequently use RWE in their scoping process

• All ICER reports of pharmaceuticals published between January 2014 and June 2019 were reviewed for the average number of instances and proportion of real-world evidence used in the scoping documents.
• In the ICER scoping documents, the mean number of instances of real-world evidence use was 3.8 per document.
• “[Real-world evidence] was frequently used in the ICER scoping process, particularly to inform selection of outcomes. [Real-world evidence] was used infrequently in ICER CCE assessments, while more often used to inform effectiveness, safety, and treatment patterns in relevant clinical guidelines”
• “There has been growing interest in using real-world evidence for health technology assessment (HTA) in the United States. [ICER] is an independent US-based HTA organization that focuses primarily on pharmaceuticals”

Boshen Jiao

MPH, The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute

  Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.

About DISTILL

DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.

For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com

Ref: RWEMAR2022CWA